1ST INTERNATIONAL CONFERENCE ON PH+ LEUKEMIAS

• FAUSTO CASTAGNETTI· DIRIGENTE MEDICO
• CRISTINA PAPAYANNIDIS· DIRIGENTE MEDICO

• ELISABETTE ABRUZZESE· MODERATORE
• GIANNI BINOTTO· MODERATORE
• MONICA BOCCHIA· MODERATORE
• MASSIMILIANO BONIFACIO· RELATORE
• MASSIMO BRECCIA· RELATORE
• GIOVANNI CAOCCI· RELATORE
• FAUSTO CASTAGNETTI· RELATORE
• MARCO CERRANO· MODERATORE
• SABRINA CHIARETTI· RELATORE
• DANIELA CILLONI· MODERATORE
• ANTONIO CURTI· RELATORE
• CARMEN FAVA· RELATORE
• VALENTIN GARCIA-GUTIERREZ· RELATORE
• FRANCESCO GRIMALDI· MODERATORE
• ILARIA IACOBUCCI· RELATORE
• ELIAS J. JABBOUR· RELATORE
• RATHANA KIM· RELATORE
• FEDERICO LUSSANA· RELATORE
• KATERINA MACHOVA POLAKOVA· RELATORE
• GIOVANNI MARTINELLI· RELATORE
• DRAGANA MILOJKOVIC· RELATORE
• FRANCK EMMANUEL NICOLINI· RELATORE
• FABRIZIO PANE· MODERATORE
• CRISTINA PAPAYANNIDIS· RELATORE
• ALESSANDRO RAMBALDI· RELATORE
• CLAIRE RODDIE· RELATORE
• GIANANTONIO ROSTI· RELATORE
• DOMENICO RUSSO· MODERATORE
• SIMONA SOVERINI· RELATORE
• FABIO STAGNO· MODERATORE
• MARIO TIRIBELLI· RELATORE
• PIER LUIGI ZINZANI· MODERATORE

Ragione sociale

STUDIO E.R. CONGRESSI S.R.L.

Stato accreditamento

STANDARD - 1° rinnovo

Di sistema

The identification of philadelphia chromosome and the characterization of the hybrid bcr::abl1 gene has marked a modern era in the treatment of cml and all, thanks to the development of tyrosine kinase inhibitors and their introduction in the therapeutic armamentarium, which led to a significant improvement of patients' outcome and quality of life. Nevertheless, many open questions are still unsolved, covering biological issues and therapeutic strategies in both diseases, in which the same molecular alteration gives rise to different leukemias, in terms of biological complexity, clinical presentation, treatment and prognosis. The aim of the meeting is to share the most recent novelties in the field, pointing out the unmet needs and the current and future strategies for a deeper understanding of cml and ph+ all, and a more successful therapeutic approach.

#2Linee guida - protocolli - procedure

Area: Obiettivi formativi tecnico-professionali

Partecipanti max

120

Verifica presenza

Firma Di Presenza

Verifica apprendimento

Questionario A Risposta Multipla